​

Immunome (IMNM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IMNM Stock Forecast

Immunome (IMNM) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $30.33, with a high of $35.00 and a low of $23.00. This represents a 283.44% increase from the last price of $7.91.

$5 $11 $17 $23 $29 $35 High: $35 Avg: $30.33 Low: $23 Last Closed Price: $7.91

IMNM Stock Rating

Immunome stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

IMNM Price Target Upside V Benchmarks

TypeNameUpside
StockImmunome283.44%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$23.00
Last Closing Price$7.91$7.91$7.91
Upside/Downside--190.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2526---8
Mar, 2525---7
Feb, 2525---7
Jan, 2525---7
Dec, 2425---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 13, 2024Biren AminPiper Sandler$23.00$12.6481.96%190.77%
Apr 15, 2024Michael SchmidtGuggenheim$35.00$20.5870.07%342.48%
Apr 01, 2024David NierengartenWedbush$33.00$24.6833.71%317.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 14, 2024Piper SandlerOverweightOverweighthold
Sep 16, 2024Cowen & Co.BuyBuyhold
Aug 13, 2024Piper SandlerOverweightOverweighthold
May 31, 2024Piper SandlerOverweightinitialise
Apr 15, 2024GuggenheimBuyinitialise
Apr 01, 2024WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.69$-5.38$-5.00----
Avg Forecast$-8.63$-0.92$-4.42$-3.11$-3.21$-2.81$-1.32
High Forecast$-3.99$-0.47$-4.32$-2.48$-2.36$-1.72$-1.01
Low Forecast$-15.99$-1.19$-4.56$-4.10$-4.36$-3.97$-1.63
Surprise %-80.42%484.78%13.12%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$14.02M$9.04M----
Avg Forecast$2.10M$12.27M$9.41M$3.15M$17.90M$76.14M$223.12M
High Forecast$3.48M$14.02M$11.40M$3.71M$17.90M$76.14M$262.84M
Low Forecast$1.23M$10.50M$7.56M$2.58M$17.90M$76.14M$183.11M
Surprise %-14.28%-3.89%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-17.12M$-106.81M$-292.96M----
Avg Forecast$-171.25M$-16.47M$-88.13M$-65.26M$-66.63M$-56.45M$-26.19M
High Forecast$-79.25M$-9.41M$-85.78M$-49.16M$-46.75M$-34.13M$-20.09M
Low Forecast$-317.26M$-23.53M$-90.47M$-81.35M$-86.51M$-78.77M$-32.26M
Surprise %-90.00%548.56%232.44%----

IMNM Forecast FAQ

Is Immunome stock a buy?

Immunome stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immunome is a favorable investment for most analysts.

What is Immunome's price target?

Immunome's price target, set by 6 Wall Street analysts, averages $30.33 over the next 12 months. The price target range spans from $23 at the low end to $35 at the high end, suggesting a potential 283.44% change from the previous closing price of $7.91.

How does Immunome stock forecast compare to its benchmarks?

Immunome's stock forecast shows a 283.44% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Immunome over the past three months?

  • April 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Immunome’s EPS forecast?

Immunome's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.11, marking a -37.80% decrease from the reported $-5 in 2024. Estimates for the following years are $-3.21 in 2026, $-2.81 in 2027, and $-1.32 in 2028.

What is Immunome’s revenue forecast?

Immunome's average annual revenue forecast for its fiscal year ending in December 2025 is $3.15M, reflecting a -65.18% decrease from the reported $9.04M in 2024. The forecast for 2026 is $17.9M, followed by $76.14M for 2027, and $223.12M for 2028.

What is Immunome’s net income forecast?

Immunome's net income forecast for the fiscal year ending in December 2025 stands at $-65.257M, representing a -77.73% decrease from the reported $-293M in 2024. Projections indicate $-66.63M in 2026, $-56.449M in 2027, and $-26.194M in 2028.